Global Idiopathic Pulmonary Fibrosis Market Analysis & Industry Forecast 2017-2023, With an Expected CAGR of Almost 12% - ResearchAndMarkets.com

June 8, 2018

DUBLIN--(BUSINESS WIRE)--Jun 8, 2018--The “Idiopathic Pulmonary Fibrosis Market by Type of Drug - Global Opportunity Analysis and Industry Forecast, 2017-2023” report has been added to ResearchAndMarkets.com’s offering.

The global idiopathic pulmonary fibrosis market generated $1,616 million in 2016, and is projected to reach $3,569 million by 2023, registering a CAGR of 11.9% during the study period.

Idiopathic pulmonary fibrosis is a condition in which the tissues in the lungs become thick and stiff over time. As a result of thickening of lung tissues, brain and other organs are unable receive optimum oxygen.

The major factors that drive the growth of the global idiopathic pulmonary fibrosis market include rise in prevalence of fibrotic disease and increase in geriatric population. In addition, surge in demand for cost-effective drugs and introduction of advanced treatment options propel the market growth. However, unavailability of the proper treatment options of the disease restricts the market growth.

The global idiopathic pulmonary fibrosis market is segmented on the basis of type of drug and region. According to type of drug, the market is divided into pirfenidone and nintedanib. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Companies Mentioned:

MediciNova, Inc. Boehringer Ingelheim F. Hoffmann-La Roche FibroGen, Inc. Promedior, Inc. Merck & Co., Inc. Galapagos NV Biogen Bristol-Myers Squibb Company Prometic Life Sciences Inc. Cipla Inc.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Executive Summary

Chapter 3 Market Overview

Chapter 4 Global Idiopathic Pulmonary Fibrosis Market, By Drug Type

Chapter 5 Idiopathic Pulmonary Fibrosis Market, By Region

Chapter 6 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/4gg3r6/global_idiopathic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180608005345/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Respiratory Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/08/2018 08:40 AM/DISC: 06/08/2018 08:40 AM


Update hourly